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Abstract 
Background: A systematic review suggests that 25% of oesophageal adenocarcinomas (OAC) are 
‘missed’ at index endoscopy for Barrett’s oesophagus (BO), however this included few population-
based studies and may be an overestimate. 
Objective: To quantify the ‘missed’ rates of high-grade dysplasia (HGD) and OAC at index BO 
endoscopy.  
Methods: Patients from the Northern Ireland BO register diagnosed between 1993-2010 (n=13,159) 
were linked to the Northern Ireland Cancer Registry to identify patients who developed OAC or HGD. 
Logistic regression analysis compared characteristics of ‘missed’ versus ‘incident’ HGD/OAC, defined 
as diagnoses within 3-12 months versus >1 year after incident BO, respectively.  
Results: 267 patients were diagnosed with HGD/OAC ≥3 months after BO diagnosis, of which 34 
(12.7%) were potentially ‘missed’. The proportion of ‘missed’ HGD/OAC was 25% among BO patients 
with low-grade dysplasia (LGD) and 9% among non-dysplastic BO patients. Older age and BO-LGD 
carried a higher risk of ‘missed’ HGD/OAC. Non-dysplastic BO patients were more often diagnosed 
with a ‘missed’ OAC (rather than HGD; 89%), compared with BO-LGD patients (40%). 
Conclusions: Approximately 1 in 10 HGD/OAC cases are ‘missed’ at incident BO diagnosis, which is 
significant but lower than previous reports. However ‘missed’ HGD/OAC cases represent only 0.26% 
of all BO patients. 
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Key summary 
 
1. Established knowledge on this subject 
 A systematic review suggests that 25% of oesophageal adenocarcinomas (OAC) are ‘missed’ 
at index endoscopy for Barrett’s oesophagus (BO), however this review was severely lacking 
inclusion of robust, population-based data and included diagnoses within three months after 
the index BO endoscopy in their definition of a ‘missed’ cancer. Both of these considerations 
are likely to have resulted in an overestimate of the magnitude of ‘missed’ cancers. 
 By performing one of the largest population-based studies to date we aimed to quantify the 
‘missed’ rates of high-grade dysplasia (HGD) and OAC at index BO endoscopy. 
2. Significant findings of this study 
 We defined a ‘missed’ case as being diagnosed with HGD/OAC within 3-12 months after 
index BO diagnosis  
 Results showed a ‘missed’ HGD/OAC rate of 13%, approximately 1 in 10, at incident BO 
diagnosis which is not negligible, but is substantially lower than rates suggested by a recent 
systematic review of this area.  
 Increased awareness, adequate biopsy sampling and identifying biomarkers may reduce the 
number of BO patients with a ‘missed’ oesophageal malignant or premalignant lesion.   
 However, such efforts must be balanced in the context of ‘missed’ cases representing a small 
minority of the overall BO patient population.  
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Introduction 
Barrett’s oesophagus (BO) is currently the only known precursor for oesophageal adenocarcinoma 
(OAC), which has a poor prognosis with five year survival rates between 15% and 20% 1.  Although 
the incidence of BO and OAC are increasing in the Western world, only approximately 0·4% of BO 
patients will progress to OAC each year 2-5. This raises issues for how to manage the increasing 
number of patients with BO and how to identify high-risk patients, without overburdening services. 
 Endoscopic surveillance is recommended in BO patients to reduce morbidity and mortality 
through early detection of dysplasia and cancer 6, 7. The British Society of Gastroenterology (BSG) 
guidelines recommends repeated endoscopy at 3-5 year intervals among BO patients with a Barrett’s 
length of under three cm,  and repeated endoscopy at 2-3 year intervals is recommended for patients 
with longer Barrett’s segments or specialised intestinal metaplasia (SIM) 6 . Patients with low-grade 
dysplasia (LGD) should receive surveillance endoscopy at six monthly intervals. However, as of 2015, 
endoscopic ablation, preferably with radiofrequency ablation (RFA), was recommended for high-grade 
dysplasia (HGD) or LGD diagnosed on two occasions in addition to repeat surveillance endoscopy at 
six months for patients with LGD 6. In spite of relatively intensive surveillance, the impact of these 
programs on preventing deaths from OAC is equivocal 8-10.  A contributing problem for the optimal 
management of BO surveillance is the occurrence of ‘interval’ and ‘missed’ cancers 11, 12. 
 ‘Missed’ cancers can be defined as cancers that were already present at the index BO 
endoscopy, but were not detected, whereas it is hypothesised that truly incident cancers develop after 
the index BO endoscopy 13, 14. A recent systematic review found that amongst BO patients, 25% of 
patients who later developed OAC, were diagnosed within one year after index BO endoscopy, and 
could be therefore be considered ‘missed’ cancers 14. However, this review included only a few 
population-based studies and included diagnoses within three months after the index BO endoscopy 
in their definition of a ‘missed’ cancer. Both of these considerations are likely to have resulted in an 
overestimate of the magnitude of ‘missed’ cancers. Therefore, this study aimed to quantify the 
‘missed’ rates of HGD and OAC at index endoscopy among patients with a BO diagnosis utilizing one 
of the largest population-based registers of BO worldwide. We further sought to identify risk factors 
which may contribute to these missed cases. 
 
6 
 
Methods 
BO patients 
The Northern Ireland Barrett’s register (NIBR) includes 13,294 patients with BO aged ≥ 16 years 
diagnosed between 1993 and 2010 in Northern Ireland (population of 1.8 million). Descriptions of the 
NIBR have been previously reported 4.  Strict criteria for BO were used, which was defined as 
columnar-lined epithelium of the oesophagus. Trained staff extracted information on BO length, the 
presence of SIM and visible BO at endoscopy, using standardised guidelines, from all pathology 
reports relating to oesophageal biopsies carried out in Northern Ireland over this time period. The date 
of the earliest (index) biopsy showing BO was taken as the date of entry into the register.  
 
Outcomes 
The NIBR was matched to the Northern Ireland Cancer Registry (NICR) 15 which was used to identify 
BO patients who progressed to oesophageal or gastric cardia adenocarcinoma (hereafter referred to 
as OAC) between January 1993 and 2013 in NI. Gastric cardia adenocarcinoma was also included as 
an outcome because it is likely that these tumours in BO patients are oesophageal in origin. This 
process has been described previously 3. Histologically unspecified cancers were reviewed by a 
gastrointestinal pathologist. Oesophageal squamous cell carcinomas were excluded. Deaths were 
identified through matching to the NI Registrar General’s Office. Matching of BO patients diagnosed 
after 2005 with the NICR was performed by using the unique Health and Social Care Number, which 
is available for over 90% of patients. The remaining patients and patients diagnosed before 2005 
were matched using patients’ forename, surname and date of birth.   
 BO patients who developed HGD were identified by examining all oesophageal pathology 
reports from NI for the period 1993-2013. Patients were considered to have HGD if diagnosed twice 
within one year or in two subsequent biopsies, even if the duration between them was more than one 
year, or if HGD was present in a single biopsy and the duration of available follow-up after the 
development of HGD was less than one year. HGD which occurred in squamous epithelium was not 
included as an outcome. According to the Central Committee on Research involving Human Subjects 
(CCMO), this type of study does not require approval from an ethics committee. 
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Statistical analysis 
The primary outcome was ‘missed’ OAC and HGD after a BO diagnosis. Patients with HGD/OAC 
were divided in two categories: ‘missed’ and incident cases. In line with previous studies, ‘missed’ 
HGD/OAC was defined as diagnoses within 3-12 months after the index BO biopsy. An outcome less 
than 3 months after index BO could be part of the diagnostic work-up instead of ‘missed’ and 
therefore these patients were excluded from the analysis (n=187) 13, 16. Incident HGD/OAC was 
defined as being diagnosed at least one year after index BO biopsy.  Follow-up was defined from the 
first BO diagnosis until first HGD or OAC diagnosis and was available until 31st December 2013.  
 Data were analysed for the combined outcome of HGD and OAC, and for OAC only.  Chi-
squared tests and ANOVA were used to compare categorical and continuous variables, respectively, 
between patients diagnosed 3-12 months, one to three year and more than three year following BO 
diagnosis.  Univariable and multivariable logistic regression were used to examine factors associated 
with being diagnosed within 3-12 months after a BO diagnosis versus being diagnosed later than one 
year after BO diagnosis.  
 Two analyses were performed among a selected group of BO patients. First, restriction was 
applied to the analysis to examine differences in the proportion of ‘missed’ HGD/OAC cases in the 
period 1993-2001 and 2002-2010. Patients who progressed more than 3 years after BO diagnosis 
were excluded from this particular analysis as the maximum time of follow-up was three years for 
patients diagnosed with BO in 2010. Second, restriction was applied to the analysis to investigate 
tumour stage according to time between BO diagnosis and HGD/OAC diagnosis. As tumour stage 
was less accurately registered for BO patients who progressed to OAC before 2002, only patients 
diagnosed with BO as of 2002 were included. A secondary analysis compared median survival time 
between all ‘missed’ and incident OAC patients for which survival time was defined from OAC 
diagnosis until death or until 9th December 2016, whichever occurred earlier. Statistical analyses were 
conducted using Intercooled STATA V11.0. 
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Results   
Proportion of ‘missed’ HGD/OAC cases  
During the study period, n=267 patients developed HGD/OAC after three months of follow-up, of 
which n=34 patients (12.7%) were diagnosed within 3-12 months after BO diagnosis (Table 1). The 
proportion of HGD/OAC classified as ‘missed’ was reduced in non-dysplastic BO (9%), whereas a 
higher proportion was observed in BO-LGD (25%). When restricting analysis to OAC progressors 
only, n=210 patients developed OAC after three months of follow-up, of which n=26 patients (12%) 
were diagnosed within 3-12 months after BO diagnosis (Supplementary table 1).  The distribution of 
HGD/OAC diagnoses over time is shown in Figures 1 and 2. Figure 1 shows that approximately half 
of HGD/OAC progressors were diagnosed more than 5 years after their first BO biopsy. Furthermore, 
the proportion of non-dysplastic BO patients increases, and the proportion of LGD-BO patients 
decreases with increasing follow-up years after first BO biopsy among patients who progressed in 
HGD/OAC (Figure 2).  
Clinical factors associated with risk of ‘missed’ versus incident HGD/OAC 
Patients with a ‘missed’ HGD/OAC were significantly older compared to patients diagnosed after three 
years with HGD/OAC (median age of 66·9 vs 60·1 years; Table 1).  Approximately a quarter of the 
patients who were 75 years or older and progressed to HGD/OAC progressed within 3-12 months 
after a BO diagnosis, whereas only 9% of progressors younger than 65 years did so (P=0.008; Table 
1). In multivariable analysis, patients aged ≥75 v. <65 years still had higher odds of a ‘missed’ 
compared with incident HGD/OAC (OR= 2·78 95%CI 1·02-7·61). Overall, sex, SIM, length of Barrett’s 
segment, visible segment seen at index endoscopy and socio-economic status were not associated 
with risk of a ‘missed’ compared with incident HGD/OAC (Table 2). Similar findings were observed 
when restricted to OAC progressors only (data not shown). 
 Patients with LGD had 3.5-fold higher odds of being diagnosed within 3-12 months rather 
than incident HGD/OAC compared to non-dysplastic BO patients (OR=3·48 95%CI 1·56-7·76; Table 
2).  LGD or non-dysplastic status also influenced the severity of HGD/OAC detected within ‘missed’ 
cases. Among the BO-LGD patients, 40% developed HGD and 60% developed OAC. In contrast, 
within the non-dysplastic BO patients who developed a ‘missed’ HGD/OAC, only 11% had HGD 
detected and the majority (89%) had OAC detected (Figure 3).  
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Proportion of missed HGD/OAC by period of BO diagnosis 
We then sought to evaluate if proportions of ‘missed’ HGD/OAC diagnoses had changed over time. 
Similar proportions of HGD/OAC cases diagnosed within 3-12 months after their BO diagnosis were 
observed in the earlier 1993-2001 time period (36%) and the more recent 2002-2013 period (38%) 
(Table 3). Results indicate a higher proportion of ‘missed’ cases compared to main results in Table 1 
due to exclusion of patients diagnosed more than three years after a BO diagnosis.  
Tumour stage and survival among ‘missed’ versus incident OAC patients 
Patients diagnosed with a ‘missed’ OAC were diagnosed with an earlier or unknown tumour stage 
compared with OAC patients diagnosed after 3 years (P=0·175). Among the patients with a ‘missed’ 
OAC, 33% had a stage I tumour, whereas 27% and 18% of the patients diagnosed within 1-3 year 
and after three years, respectively, had a stage I tumour (Supplementary figure 1).  Better survival 
outcomes were also observed amongst ‘missed’ compared with incident OAC cases (median (IQR) 
survival 3.96 (0.90-9.46) and 1.94 (0.44-6.12) years, respectively).  
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Discussion 
This is one of the largest population-based studies to date to investigate the magnitude of ‘missed’ 
HGD or OAC in patients with BO. We defined a ‘missed’ case as being diagnosed with HGD/OAC 
within 3-12 months after index BO diagnosis. Results showed ‘missed’ rates of 13% and 9% among 
all BO patients and all non-dysplastic BO patients, respectively, who were subsequently diagnosed 
with HGD/OAC. The proportion of ‘missed’ cases remained stable during the study period. 
 The ‘missed’ rate reported in the present study is significant but lower than previously 
reported estimates. A systematic review of 24 studies reported a ‘missed’ rate of 25% 14.  
Furthermore, three population-based studies, which were also included in the review, reported that 
32-66% of the patients who progressed in OAC were diagnosed within one year after BO diagnosis2, 3, 
17. In contrast with our study, these studies defined ‘missed’ as being diagnosed with HGD/OAC within 
one year after BO diagnosis. However, HGD/OAC patients diagnosed less than three months after 
BO may be part of the diagnostic work-up16. Chadwick et al also excluded patients diagnosed within 
three months after a BO diagnosis for the calculation of their ‘missed’ rate13. They found that 7.8% of 
the patients with OAC underwent a previous endoscopy three to 36 months preceding diagnosis of 
OAC, which is similar to the ‘missed’ rate of 9% detected in non-dysplastic BO patients in the present 
study.  Furthermore, Holmberg et al also noted a high incidence of OAC within the first 100 days after 
BO diagnosis 16.   14. Still, it is worth noting that all of the above reported ‘missed’ rates after an 
oesophagogastroduodenoscopy are unfavourable compared with reported rates of missed colorectal 
cancers after a colonoscopy, which ranges from 0.5% to 6% 18, 19.  
 There could be two overarching explanations for the ‘missed’ cancers. First, the missed 
cancers may be truly missed, which means that the cancer or premalignant lesions were already 
present at index endoscopy but not detected. A previous study has found that errors by the 
endoscopist account for the majority (73%) of ‘missed’ oesophageal or gastric cancers at endoscopy 
and the remaining 27% were related to errors by pathologists 20. It is possible that HGD or OAC was 
not detected due to features that make them less likely to be seen by the endoscopist such as 
oesophagitis, oesophageal stricture and ulceration 20. Methods to increase detection of HGD/OAC 
such as advanced endoscopic imaging techniques 6, greater time examining BO segments 21 ,greater 
number of targeted biopsies 20 and dedicated time slots for examination 22 may identify HGD or 
malignant lesions and decrease the burden of missed HGD/OAC through early detection of 
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HGD/OAC which could increase cure and survival rates 7.  
 Cases may be truly missed if the second endoscopy was not part of routine surveillance. 
Based on a previous case note review (unpublished) among 60% of the HGD/OAC progressors, more 
than half of the ‘missed’ cases were not entered into routine surveillance and surveillance was 
probably performed due to new symptoms. These cases may be truly ‘missed’ cases. Moreover, 
taking into account the time interval between BO and OAC, one can suggest that the OAC cases 
were already present at index endoscopy. Nevertheless,the missed cases represents only 0.26% of 
all BO patients diagnosed in NI over this timeframe, and so the ever-important question of identifying 
the very small proportion of high-risk patients ( ‘missed’ or incident HGD/OAC) remains a 
considerable challenge.   
 Second, it is plausible that the missed cancers may be more aggressive cancers which have 
no visible evidence at index endoscopy but develop rapidly afterward. Therefore, biomarkers could 
assist in determining the risk of progression at BO diagnosis and guide the targeting of endoscopic 
surveillance23 . Previous studies indicate that there are two main pathways of progression among BO 
patients 24, 25. A more indolent pathway which moves through to dysplasia to OAC, acquiring a variety 
of mutations and a more aggressive pathway dominated by genomic doubling with more frequent 
oncogenic amplification and less frequent inactivation of tumour suppressors24. Results from the 
present study provide some support for these two pathways, as non-dysplastic BO patients were 
more often diagnosed with ‘missed’ OAC than ‘missed’ HGD compared to LGD patients. However, the 
present study has found that patients diagnosed within 3-12 months after BO diagnosis had more 
often a stage I or stage II tumour and a longer median survival compared to patients diagnosed more 
than three year after BO diagnosis. Patients with a missed OAC had a better median survival 
probably because they had more often an earlier tumour stage which can effectively be treated with 
endoscopic techniques such as endoscopic resection and RFA. 
 A higher ‘missed’ rate of 25% among LGD-BO patients likely reflects appropriate clinical 
management and planned surveillance after BO diagnosis. Results of the present study support the 
effectiveness of BSG guidelines, which recommend more frequent surveillance endoscopy among 
LGD-BO patients, as these patients had a higher likelihood to have HGD/OAC diagnosed within 3-12 
months, compared to non-dysplastic BO patients. This conclusion is supported by the proportion of 
‘missed’ HGD cases among all ‘missed’ HGD/OAC cases being higher among patients with LGD-BO 
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compared with non-dysplastic BO (60% vs 11%). Our study timelines pre-date the recent changes to 
BSG guidelines6 to allow endoscopic ablation, preferably with RFA, for LGD patients, instead of 
repeated endoscopy after six months of being treated with proton pump inhibitors (PPIs) 6, 26, 27.   
 We also explored if clinical or demographic features may differ between ‘missed’ or incident 
HGD/OAC cases. Having an older age was associated with a higher risk of a ‘missed’ HGD/OAC 
instead of an incident HGD/OAC. It is possible that simply the older you are the more likely you are to 
have cancer and therefore the more likely for it to be missed. However, higher rates of ‘missed’ cases 
among elderly patients may simply reflect shorter life expectancies and therefore a reduced likelihood 
of developing HGD/OAC 3 years after first BO biopsy . In addition, a previous study from Visrodia et 
al found that the presence of a long-segment BO could  place patients at greater risk of ‘missed’ HGD 
or OAC 28.  In contrast, the  length of Barrett’s segment was not associated with a higher risk of a 
‘missed’ HGD or OAC in the present study. However, information on Barrett’s length was limited in our 
cohort.  
 This study has important strengths. In particular the completeness of identification of 
outcomes, large size and population-based analysis within a region with limited migration 15.  
However, this study also has some limitations. The exclusion of patients diagnosed within three 
months for the definition of ‘missed’ cases is somewhat arbitrary. However, a previous study also 
excluded these patients as a diagnosis within three months after BO diagnosis could be part of the 
diagnostic work-up13. Furthermore, BO guidelines have been updated since conclusion of this study 
period. Within the updated BSG guidelines published in 2015, clinicians can now discharge patients 
from endoscopic surveillance who have a short Barrett’s segment and repeated confirmation that SIM 
is not present 6. Therefore, future research may need to reassess these estimates to evaluate any 
impact on potential ‘missed’ diagnoses, however, the perceived low cancer risk in these patients is 
likely to have minimal influence. Finally, we acknowledge that the term ‘missed’ is somewhat 
controversial in the capacity of this, and similar, studies. We retained the term in this report primarily 
to ensure comparability with previous publications.  However, we call on researchers to adopt a more 
appropriate term, such as underdiagnosed or short-term interval cancers, for future manuscripts.    
 In conclusion, based upon a large population-based study, we observed  a ‘missed’ 
HGD/OAC rate of 13%, which is not negligible, but is substantially lower than rates suggested by a 
recent systematic review of this area 14. Increased awareness, adequate biopsy sampling and 
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identifying biomarkers may reduce the number of BO patients with a ‘missed’ oesophageal malignant 
or premalignant lesion.  However, such efforts must be balanced in the context of ‘missed’ cases 
representing a small minority of the overall BO patient population. 
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Table 1: Characteristics of patients with a Barrett’s oesophagus who progressed to HGD/ OAC after 3 
months after a Barrett’s diagnosis (n=267)  
Features at index BO 
endoscopy * 
HGD/OAC 
progressors  
≥ 3-12 months 
N=34 (13%)  
 
 
HGD/OAC 
progressors within 
≥ 1-3 year  
N=59 (22%) 
HGD/OAC 
progressors  
≥ 3 years 
N=174 (65%) 
P value 
 N % ** N % ** N % **  
Sex       0.601 
   Female 8 11.76 18 26.47 42 61.76  
   Male 26 13.07 41 20.60 132 66.33  
Median age( IQR) 66.9 60.7-75.3 65.2 56.7-73.7 60.1 52.3-68.3 <0.001 
Age group       0.008 
   <65 15 9.15 29 17.68 120 73.17  
   65-74 10 15.38 20 30.77 35 53.85  
   ≥75 9 23.68 10 26.32 19 50.00  
Socio-economic status a       0.146 
   Most deprived 16 15.53 16 15.53 71 68.93  
   Middle deprived 7 13.73 8 15.69 36 70.59  
   Least deprived 9 9.68 29 31.18 55 59.14  
   Unknown 2 10.00 6 30.00 12 60.00  
Specialised intestinal 
metaplasia      
  0.412 
   Absent / unknown 9 14.75 14 22.95 38 62.30  
   Present 25 12.14 45 21.84 136 66.02  
Visible segment seen at 
endoscopy     
  0.843 
   Unknown/no 22 13.02 39 23.08 108 63.91  
   Yes 12 12.24 20 20.41 66 67.17  
Dysplasia       <0.001 
   No dysplasia  19 9.13 40 19.23 149 71.63  
   Low-grade dysplasia 15 25.42 19 32.20 25 42.37  
a Category ‘most deprived quintile’ and ‘quintile 2’ are merged into ‘most deprived’. Category ‘quintile 
4’ and ‘Least deprived quintile’ were merged into ‘Least deprived’. 
* Numbers for short, long and unknown Barrett’s segment are not presented due to small cell counts 
(<3) and to avoid disclosure of potentially identifiable information.  
** Percentages were calculated across the rows to emphasise the proportions of all missed or incident 
cancers over time, rather than calculating the percentages within the columns. 
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Table 2: Univariable and multivariable logistic regression analysis to examine the likelihood of being 
diagnosed with HGD/ OAC after 3-12 months compared to ≥ 1 year after a Barrett’s oesophagus 
diagnosis (n=267). 
Features at index BO 
endoscopy 
3-12 
months 
≥ 1 
year  
Univariable Multivariable* 
 N=34 N=233 OR 95%CI OR 95%CI 
Sex       
   Female 8 60 ref  ref  
   Male 26 173 1.13 0.48-2.62 1.31 0.51-3.33 
Age group       
   <65 15 149 ref  ref  
   65-74 10 55 1.81 0.77-4.26 1.90 0.77-4.67 
   ≥75 9 29 3.08 1.23-7.71 2.78 1.02-7.61 
Socio-economic status a       
   Most deprived 16 87 ref  ref  
   Middle deprived 7 44 0.87 0.33-2.26 1.10 0.39-3.06 
   Least deprived 9 84 0.58 0.24-1.39 0.62 0.25-1.54 
   Unknown 2 18 0.60 0.13-2.86 0.75 0.15-3.79 
Specialised intestinal 
metaplasia       
 
   Absent / unknown 9 52 ref  ref  
   Present 25 181 0.80 0.35-1.82 0.76 0.31-1.83 
Visible segment seen at 
endoscopy      
 
   No / unknown 22 147 ref  ref  
   Yes 12 86 0.93 0.44-1.98 0.97 0.42-2.27 
Length of Barrett’ s 
segment**      
 
   Long ≥ 3 cm   NR NR 0.54 0.09-3.03 0.53 0.08-3.29 
   Short < 3 cm NR NR ref  ref  
   Unknown 27 148 1.37 0.30-6.33 1.44 0.27-7.77 
Dysplasia at index biopsy       
   No dysplasia  19 189 ref  ref  
   Low-grade dysplasia 15 44 3.39 1.60-7.20 3.48 1.56-7.76 
NR= not reported 
a Category ‘most deprived quintile’ and ‘quintile 2’ are merged into ‘most deprived’. Category ‘quintile 
4’ and ‘Least deprived quintile’ were merged into ‘Least deprived’.  
* Adjusted for all variables listed in table 3. 
** Numbers for short and long Barrett’s segment are not presented due to small cell counts (<3) and 
to avoid disclosure of potentially identifiable information. 
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Table 3 Proportion of ‘missed’  HGD or OAC according to period of Barrett’s diagnosis among 
patients who progressed in HGD or OAC within 3-36 months after their Barrett’s diagnosis. * 
 Diagnosed 3-12 months 
after BO diagnosis 
N=34 
Diagnosed ≥1-3 year 
after BO diagnosis 
N=59 
P value** 
Period of BO diagnosis   0.835 
   1993-2001 20 (36%) 36 (64%)  
   2002-2010 14 (38%) 23 (62%)  
* Patients diagnosed more than 3 year after a BO diagnosis were excluded from the analysis as the 
maximum follow-up is 3 year for BO patients diagnosed in 2010. 
**based on a chi-squared test.
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Figure 1: Distribution of time to oesophageal adenocarcinoma or high-grade dysplasia (OAC/HGD) 
diagnosis among 267 detected cases of OAC/HGD. 
BO=Barrett’s oesophagus  
 
Figure 2 Dysplasia status at Barrett’s oesophagus diagnosis by time to OAC/HGD  diagnosis among 
267 detected cases of OAC/HGD. 
 
Figure 3 Progression in HGD/OAC according to dysplasia status among 34 ‘missed’ cases of 
HGD/OAC. 
 
Supplementary figure 1: Tumour stage and time until oesophageal adenocarcinoma (OAC) 
diagnosis for patients with a Barrett’s oesophagus diagnosed between 2002 and 2010 that 
progressed in OAC (n=76).  
Patients diagnosed with a BO before 2002 and progressed in OAC were excluded from the analysis 
as their tumour stage was less accurately reported.
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Supplementary table 1 Characteristics of patients with a Barrett’s oesophagus who progressed to 
OAC 3 months after a Barrett’s diagnosis (n=210)  
Features at index BO 
endoscopy * 
Patients diagnosed  
≥ 3-12 months  
N=26 (12%) 
 
Patients diagnosed  
≥ 1-3 year  
N=39 (19%) 
Patients diagnosed 
 ≥ 3 years 
N=145 (69%) 
P 
value 
 N % ** N % ** N % **  
Sex       0.424 
   Female 5 9.09 13 23.64 37 67.27  
   Male 21 13.55 26 16.77 108 69.68  
Median age( IQR) 68.2 60.7-79.1 68.4 58.4-74.5 60.7 52.5-69.2 0.007 
Age group       0.012 
   <65 11 13.11 16 13.11 95 77.87  
   65-74 7 12.96 15 27.78 32 59.26  
   ≥75 8 23.53 8 23.53 18 52.94  
Socio-economic status a        0.065 
   Most deprived 14 16.67 11 13.10 59 70.24  
   Middle deprived 6 14.29 4 9.52 32 76.19  
   Least deprived 5 7.04 21 29.58 45 63.38  
   Unknown 1 7.69 3 23.08 9 69.23  
Specialised intestinal 
metaplasia        0.723 
   Absent/ unknown 6 12.24 11 22.45 32 65.31  
   Present 20 12.42 28 17.39 113 70.19  
Visible segment seen at 
endoscopy       0.576 
   Unknown/no 17 12.50 28 20.59 91 66.91  
   Yes 9 12.16 11 14.86 54 72.97  
Dysplasia       0.001 
   No dysplasia  17 10.24 24 14.46 125 75.30  
   Low-grade dysplasia 9 20.45 15 34.09 20 45.45  
NR= not reported 
a Category ‘most deprived quintile’ and ‘quintile 2’ are merged into ‘most deprived’. Category ‘quintile 
4’ and ‘Least deprived quintile’ were merged into ‘Least deprived’.  
* Numbers for short, long and unknown Barrett’s segment are not presented due to small cell counts 
(<3) and to avoid disclosure of potentially identifiable information. 
** Percentages were calculated across the rows as it rather suits the aim of this study than calculating 
the percentages within the columns.
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Figure 1: Distribution of time to HGD/OAC diagnosis among 267 detected cases of HGD/OAC.  
 
Figure 2 Dysplasia status at BO diagnosis by time to HGD/OAC diagnosis among 267 detected cases 
of HGD/OAC. 
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Figure 3 Progression in HGD/OAC according to dysplasia status among 34 ‘missed’ cases of 
HGD/OAC. 
0
10
20
30
40
50
60
70
80
90
100
No dysplasia Low‐grade dysplasia
Pe
rce
nta
ge 
(%
)
Dysplasia at BO diagnosis
HGD
OAC
19 15
24 
 
 
Supplementary figure 1: Time until OAC diagnosis for patients with a Barrett’s oesophagus 
diagnosed between 2002 and 2010 that progressed in OAC (n=76).  
Patients diagnosed with a BO before 2002 and progressed in OAC were excluded from the analysis as their 
tumour stage was less accurately reported.
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